Loading clinical trials...
Loading clinical trials...
A Long-Term, Open-Label Extension Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Children's Hospital Colorado
Aurora, Colorado, United States
University of Iowa Children's Hospital
Iowa City, Iowa, United States
Tufts Medical Center
Boston, Massachusetts, United States
Columbia University
New York, New York, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
St. Jude Children's Research Hospital
Memphis, Tennessee, United States
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
University of Cambridge
Cambridge, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Start Date
November 10, 2025
Primary Completion Date
April 15, 2028
Completion Date
April 15, 2028
Last Updated
February 10, 2026
25
ESTIMATED participants
Bivamelagon
DRUG
Lead Sponsor
Rhythm Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02664441